Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Marker Therapeutics ( (MRKR) ) just unveiled an update.
On June 16, 2025, Marker Therapeutics entered into a collaboration with Cellipont Bioservices for the manufacturing of MT-601, a Multi-Antigen Recognizing T cell therapy, to support the APOLLO study. This partnership aims to accelerate clinical supply and prepare for a potential pivotal trial, reflecting a significant step in advancing MT-601 for patients with lymphoma who have relapsed after or are ineligible for anti-CD19 CAR-T cell therapy.
The most recent analyst rating on (MRKR) stock is a Buy with a $12.50 price target. To see the full list of analyst forecasts on Marker Therapeutics stock, see the MRKR Stock Forecast page.
Spark’s Take on MRKR Stock
According to Spark, TipRanks’ AI Analyst, MRKR is a Neutral.
Marker Therapeutics is positioned in the biotechnology industry, characterized by high potential but also significant risks. The company exhibits strong revenue growth but faces challenges with profitability and cash flow. Technical indicators present a mixed outlook, with some potential for price reversals. The valuation reflects typical industry dynamics, favoring growth over profitability. Investors should be cautious, focusing on the company’s ability to manage cash flow and improve operational efficiencies to support future growth.
To see Spark’s full report on MRKR stock, click here.
More about Marker Therapeutics
Marker Therapeutics, Inc. is a clinical-stage immuno-oncology company based in Houston, TX, specializing in developing next-generation T cell-based immunotherapies for hematological malignancies and solid tumors. Founded at Baylor College of Medicine, the company focuses on introducing novel T cell therapies to improve patient outcomes, supported by non-dilutive funding from U.S. state and federal agencies.
Average Trading Volume: 106,033
Technical Sentiment Signal: Sell
Current Market Cap: $17.2M
See more data about MRKR stock on TipRanks’ Stock Analysis page.